Hengrui Medicine:Updates on middle/late-stage pipeline

类别:公司研究 机构:德意志银行 研究员:Jack Hu 日期:2017-10-11

Multiple catalysts ahead; late-stage pipeline represents 17% market cap by DBe.

    We update pipeline progress following the meeting with Chairman Sun. Majorcatalysts are: 1) approval of 19K and Abraxane generic by YE17; 2) resubmissionof retagliptin in the near term; 3) clarity on pyrotinib development, includingan earlier submission of marketing approval; 4) updates on clinical progressfor camrelizumab; and 5) phase 3 data release on Incyte's ECHO-301. We alsohighlight potential upside from additional US IND approval and clinical progressof its novel compounds in the US. Our NPV analysis indicated the pipeline valueis RMB9.2 per share. This comprehensive report includes key ongoing clinicalstudies for all mid/late study compounds, as well as competitors' studies.

    Camrelizumab as the largest driver; IDO inhibitor provides significant upside.

    We have updated our peak sales for camrelizumab to RMB5-6bn in China andincreased the probability of success to 75-85%, based on the strong ORR datafrom the phase 1 study. Four registration trials are being conducted at present.

    We expect Hengrui to get the first domestic PD-1 approval, with safe data fromsufficient number of patients required by the CFDA. Additionally, we expect INDapproval for its IDO inhibitor from CFDA in the near term, following US INDapproval in May. We believe it would be significantly positive to the IO franchiseand we forecast RMB3-4bn peak sales for the IDO inhibitor.

    DB proprietary patient-based PD-1/PD-L1 model.

    Our model indicates that the addressable market for PD-1/PD-L1 would beRMB19bn in China in 2017 and RMB29bn in 2030, representing a CAGR of 15%.

    NSCLC and GC are likely to be the largest indications due to a large patient baseand unmet medical need. Our model is based on 14 tumor types, including theapproved indications and major indications being investigated. Among domesticnames, we identified six companies that are conducting late stage studies fortheir PD-1/PD-L1 with Hengrui being the leader.

    Valuation and risks.

    Our current valuation for the late stage pipeline represents 17% of the market cap,vs. 15% as of our first attempt in September 2016. Our TP of RMB58.5 is basedon 42x 2018E EPS. We believe 42x is justified, as A-share peers are trading at 29xwith 18% EPS growth in 2017 (vs. the 24% we model for Hengrui). We believethe premium is justified, given the top China pipeline, major upside from exportsand the potential earnings growth acceleration driven by blockbuster launches.

    Key risks include product launch delays and price cuts.

股票代码 股票名称 最新价(元) 涨跌额(元) 涨跌幅(%) 成交额(万元) 成交量(手)
600278 @nn@ @n@ @c@ @cc@ @v@ @t@



新城控股 买入 42.49 研报
光大嘉宝 买入 7.59 研报
绿地控股 买入 9.28 研报
蓝光发展 买入 8.19 研报
金地集团 持有 15.12 研报
华夏幸福 买入 41.60 研报
新湖中宝 买入 4.18 研报
保利地产 买入 16.80 研报
世联行 买入 5.52 研报
滨江集团 买入 5.85 研报
荣盛发展 买入 13.20 研报


绿地控股 0.55 0.30 研报
新城控股 0 0 研报
光大嘉宝 0.60 0 研报
世联行 0.84 0.62 研报
大悦城 0.30 0.27 研报
蓝光发展 0.24 0 研报
荣盛发展 0.75 1.04 研报
金科股份 1.15 1.24 研报
中南建设 0.80 0.99 研报
金融街 0.64 0.72 研报
新湖中宝 0.38 0.32 研报


五粮液 36 持有 买入
泸州老窖 31 持有 买入
伊利股份 29 持有 买入
隆基股份 29 买入 买入
长安汽车 29 买入 买入
晶盛机电 27 持有 中性
三一重工 26 持有 持有
中国太保 26 持有 中性
万科A 26 买入 买入
格力电器 26 买入 买入
当升科技 26 持有 买入
中国国旅 25 持有 买入
中信证券 24 持有 中性
上汽集团 24 买入 持有
贵州茅台 24 持有 买入
恒立液压 24 持有 买入
贵州茅台 23 持有 买入


电子信息 464 76 284
电子器件 352 50 222
汽车制造 333 32 177
金融行业 287 24 140
机械行业 281 39 116
建筑建材 278 47 153
生物制药 254 37 173
酿酒行业 230 16 112
化工行业 209 42 96
房地产 197 21 145
交通运输 191 24 91
家电行业 172 15 117
钢铁行业 165 30 85
食品行业 165 24 63
商业百货 165 29 94
其它行业 141 14 85
有色金属 139 37 55